GINA KELLEY: Open Payments
NPI 1043078041 · WALLINGFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,972 in 157 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $1,695 · 2025 $2,972
Food & beverage: $2,972
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 51 | $784 |
| Ardelyx, Inc. | 23 | $345 |
| Madrigal Pharmaceuticals | 6 | $255 |
| Gilead Sciences, Inc. | 10 | $232 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $225 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $190 |
| Lilly USA, LLC | 9 | $190 |
| Aimmune Therapeutics, Inc. | 9 | $183 |
| Phathom Pharmaceuticals, Inc. | 11 | $133 |
| QOL Medical, LLC | 3 | $99 |
Products named: IBSRELA, LINZESS, REZDIFFRA, RINVOQ, ZENPEP, ENTYVIO, SKYRIZI, VOQUEZNA.
Industry payments across CT — which companies pay providers there.
